𝛼SK or SearchIPO Databook: Shenzhen Salubris Pharmaceuticals (002294 HK) - Sep 2026
114 Views05 Sep 2026 10:02
SUMMARY
- A leading Chinese pharmaceutical company focused on the CKM sector, engaged in R&D, production, and sales of pharmaceuticals and medical devices. It seeks a primary HKEX listing, having been listed.
- The company ranked second in China's in-hospital cardiovascular drug sales with 11.3% market share in 2025. Total revenue increased to RMB4,352.7 million in 2025.
- Gross profit was 3,247,584 RMB'000 and profit for the year was 652,784 RMB'000 in 2025. Total assets reached 11,297,803 RMB'000 as of December 31, 2025.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- IPO Databook: Shenzhen Salubris Pharmaceuticals (002294 HK) - Sep 202605 Sep 2026
x